<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">

EORTC 2018

Patient-derived xenograft (PDX) models from metastatic castration-resistant prostate cancer (mCRPC) patients reflect clinical disease and therapeutic outcomes



Daniel Ciznadija, PhD1, Peter Kipp, PhD1, Manish Kohli, PhD2, Swetha Tati, PhD1, Maria Mancini, PhD1, and Angela Davies, PhD1*
1Champions Oncology, USA. 2 Mayo Clinic, USA. * Current affiliation: Celgene, USA



Prostate cancer (PC) is a leading cause of cancer-related mortality in men and prognosis for mCRPC remains poor despite the availability of novel therapies including androgen receptor (AR) pathway inhibitors. Integration of drug screening and sequencing in PDX models may allow for precision medicine in mCRPC by advancing our understanding of resistance mechanisms (de novo and acquired) and identification of clinical response biomarkers. Here we highlight a cohort of PDX models developed from the bone metastases of mCRPC patients and demonstrate alignment of genomic features with clinical genetics as well as recapitulation of parent tumor histology and patient responses to therapy.